Lundbeck aims Lexapro at Chinese market; SurModics to pursue options for pharma biz;

@FiercePharma: Status update: Pharma skeptical of social media. Report | Follow @FiercePharma

> Danish drugmaker Lundbeck said it would start marketing its key antidepressant in China and its local partner would also boost sales efforts, in what it expects to be a major growth center. Article

> SurModics appointed a new chief executive as it separately said it planned to explore "strategic alternatives" for its SurModics Pharmaceuticals subsidiary, which could include a sale. Story

> Indian drug firm Strides Arcolab cancelled its licensing and supply agreement with U.S.-based KV Pharmaceuticals and will pay $7.25 million as part of settlement. Article

> Attorneys for Wyeth (now part of Pfizer) are requesting a rehearing of a Nevada Supreme Court opinion that upheld an $80.7 million award to three women who allegedly contracted breast cancer after taking a hormone drug. Report

> Union bosses who ended the pensions dispute with AstraZeneca despite failure to gain any ground say they have done their best for workers. Item

> The FDA says that Tessalon liquid cough capsules should be kept in child-proof containers because they look like candy and could pose a risk to young children if ingested. News

> Shares of Otsuka Holdings eked out a modest 2 percent gain in their debut after the drugmaker priced its record-setting $2.4 billion IPO conservatively. News

> Scottish cost regulators have stuck with their decision to bar patients with lung cancer from access to AstraZeneca's Iressa on the National Health Service, after deeming the drug too expensive. Article

> Generics maker Lannett priced a public stock offering of 5 million shares of its common stock at $5 per share. Report

> A federal judge ruled against former GC Howard Udell and two fellow drug executives who were debarred from working at companies that do business with Medicare and Medicaid, or other federal programs. Story

Biotech News

@FierceBiotech: Cell transplant gets paralyzed monkey back on his feet. Report | Follow @FierceBiotech 

 @JohnCFierce: FDA wants to encourage apps on combo drugs, using more lab/animal data in evaluations. That may work for cancer, but not for obesity, etc. | Follow @JohnCFierce

> East beats West as Big Pharma shifts R&D efforts. Item

> Sanofi, Oxford ally on new cancer research alliance in India. Story

> FDA offers new guidelines to speed combo drug programs. Article

Drug Delivery News

> How to cook up a better batch of graphene. News

> Lutonix raises $10M to develop Moxy drug-coated catheter. Report

> How to deliver drugs into a cell while doing no harm. Article

> SurModics might sell pharma unit, names new chief. Item

Medical Device News

> Thermo Fisher forks out $2.1B for Dionex. Article

> Boston Scientific drops plans to sell pain unit. News

> CR Bard losing jobs with a $20 million charge. Report

> Semprus, Sequenta raise VC cash. Report

> OsteoSymbionics gets warned by FDA. Story

> Beckman Coulter researching public vs. private future. Item

And Finally... The U.S.-raised animals we eat consumed about 29 million pounds of antibiotics in the last year alone, according to a first-ever FDA accounting of antimicrobial drug use by the American livestock industry. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.